TY  - JOUR
A1  - Assfalg, Volker
A1  - Selig, Katharina
A1  - Tolksdorf, Johanna
A1  - van Meel, Marieke
A1  - de Vries, Erwin
A1  - Ramsoebhag, Anne‐Marie
A1  - Rahmel, Axel
A1  - Renders, Lutz
A1  - Novotny, Alexander
A1  - Matevossian, Edouard
A1  - Schneeberger, Stefan
A1  - Rosenkranz, Alexander R.
A1  - Berlakovich, Gabriela
A1  - Ysebaert, Dirk
A1  - Knops, Noël
A1  - Kuypers, Dirk
A1  - Weekers, Laurent
A1  - Muehlfeld, Anja
A1  - Rump, Lars‐Christian
A1  - Hauser, Ingeborg
A1  - Pisarski, Przemyslaw
A1  - Weimer, Rolf
A1  - Fornara, Paolo
A1  - Fischer, Lutz
A1  - Kliem, Volker
A1  - Sester, Urban
A1  - Stippel, Dirk
A1  - Arns, Wolfgang
A1  - Hau, Hans‐Michael
A1  - Nitschke, Martin
A1  - Hoyer, Joachim
A1  - Thorban, Stefan
A1  - Weinmann‐Menke, Julia
A1  - Heller, Katharina
A1  - Banas, Bernhard
A1  - Schwenger, Vedat
A1  - Nadalin, Silvio
A1  - Lopau, Kai
A1  - Hüser, Norbert
A1  - Heemann, Uwe
T1  - Repeated kidney re‐transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis
JF  - Transplant International
N2  - In Eurotransplant kidney allocation system (ETKAS), candidates can be considered unlimitedly for repeated re‐transplantation. Data on outcome and benefit are indeterminate. We performed a retrospective 15‐year patient and graft outcome data analysis from 1464 recipients of a third or fourth or higher sequential deceased donor renal transplantation (DDRT) from 42 transplant centers. Repeated re‐DDRT recipients were younger (mean 43.0 vs. 50.2 years) compared to first DDRT recipients. They received grafts with more favorable HLA matches (89.0% vs. 84.5%) but thereby no statistically significant improvement of patient and graft outcome was found as comparatively demonstrated in 1st DDRT. In the multivariate modeling accounting for confounding factors, mortality and graft loss after 3rd and ≥4th DDRT (P < 0.001 each) and death with functioning graft (DwFG) after 3rd DDRT (P = 0.001) were higher as compared to 1st DDRT. The incidence of primary nonfunction (PNF) was also significantly higher in re‐DDRT (12.7%) than in 1st DDRT (7.1%; P < 0.001). Facing organ shortage, increasing waiting time, and considerable mortality on dialysis, we question the current policy of repeated re‐DDRT. The data from this survey propose better HLA matching in first DDRT and second DDRT and careful selection of candidates, especially for ≥4th DDRT.
KW  - allocation
KW  - child
KW  - fourth
KW  - graft
KW  - kidney
KW  - loss
KW  - repeated
KW  - re‐transplantation
KW  - survival
KW  - third
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-214161
VL  - 33
IS  - 6
SP  - 617
EP  - 631
ER  - 
TY  - JOUR
A1  - Fischer, W. H.
A1  - Lutz, Werner K.
T1  - Short communication : Mouse skin papilloma formation by chronic dermal application of 7,12-dimethylbenz[a]anthracene is not reduced by diet restriction
N2  - No abstract available
KW  - Toxikologie
Y1  - 1994
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60644
ER  - 
TY  - JOUR
A1  - Fischer, W. H.
A1  - Beland, P. E.
A1  - Lutz, Werner K.
T1  - DNA adducts, cell proliferation and papilloma latency time in mouse skin after repeated dermal application of DMBA and TPA
N2  - 'lbe mouse skin tumor model was used to investigate whether the Ievel of DNA 8dducts and/or the rate of cell division in the epidermis are indicators of the risk of cancer formation for an individual in an outbred animal popul8tion. A high risk was considered to be reftected by 8 short latency period for the 8ppearance of 8 papilloma. Fernale NMRI mice were treated twice weekly with 2.5 nmol 7 ,12-dimethylbenz[a]antbracene (DMBA) and 3 nmoi12-0-tetradecanoylphorbol-13- 8cetate (TPA) and the appearance of papillomas was registered. The first papilloma 8ppeared after 7.5 weeks. After 17 weeks, when 12 of 14 mice bad 8t least one papilloma, an osmotic minipump deliverlog 5-bromo-2'deoxyuridine (BrdU) was implanted into eacb mouse for 24 h. The mice were killed after 24 h ~d the epidermis was analyzed for D:MBA-nucleotide 8dducts by 32p.postlabeling, for the cell number per unit skin length, and for the labeling index for DNA synthesls. Unexpectedly, D:MBA-nucleotide 8dduct Ievels were highest in those anima1s wbich showed the Iongest latency periods. Adduct Ievels were negatively correlated with the 18beling index, indicating that dilution of adducts by cell division was a predominant factor in determining average adduct concentrations. Individual tumor-latency time was not corTelated with either cell ntunber or labeling index. This could be due to the fact that the measurements only provided 8veraged data and gave no infonnation on the specific situation in clones of premalignant cells. Under the conditions of tbis assay, therefore, neither DNA adduct Ievels nor information on the average kinetics of cell division bad a predidive value for the individual amcer risk withln a group of outbred animals receiving the same treatment
KW  - Toxikologie
Y1  - 1993
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-60673
ER  -